Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
Int J Cancer
; 153(4): 815-825, 2023 08 15.
Article
in En
| MEDLINE
| ID: mdl-37155342
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Quinolines
/
Neoplasms
Limits:
Humans
Language:
En
Year:
2023
Type:
Article